Navigation Links
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Date:7/23/2008

EAST NORRITON, Pa., July 23 /PRNewswire/ -- Tengion Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, today announced that it has appointed Mark Stejbach as Vice President, Marketing and Commercial Planning. Mr. Stejbach brings more than twenty years of marketing, sales, finance, and managed care experience from both Merck & Co., Inc. and Biogen, Inc.

"We are very pleased to welcome Mark to the Tengion executive team as we are advancing our Neo-Bladder clinical trial programs along with commercial planning activities," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of AVONEX for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will provide key insights to Tengion as we continue to grow and move our clinical pipeline toward commercialization in the US and Europe."

Mr. Stejbach started his pharma career at Merck in 1987 and went on to lead marketing campaigns for VASOTEC and PROSCAR. From 1994 to 1997, Mr. Stejbach worked for Biogen, Inc. developing and executing the launch marketing plan for the company's highly successful first marketed product, AVONEX, for multiple sclerosis. He then rejoined Merck in 1997 and since that time has held numerous senior leadership positions within the company including Senior Director roles in market development, specialty sales, marketing, and investor relations; and Vice President, Sales Services prior to his most recent role of Vice President of Managed Care Marketing in Merck's United States Pharmaceutical division. Mr. Stejbach earned his MBA from The Wharton School, University of Pennsylvania, and a BS in mathematics from Virginia Tech. He was recently named a 2008 Emerging Pharma Leader by Pharmaceutical Executive magazine.

"I am thrilled to join Tengion at what is an extremely exciting time for the company," commented Mr. Stejbach. "As Tengion continues to advance its Neo-Bladder Augment, Conduit and Replacement programs, I look forward to helping the Company achieve its ultimate goal of successfully bringing unique and compelling medical advances to patients in need."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
2. Tengion Appoints Jeff Randall to Board of Directors
3. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
5. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
6. AMT Appoints Director Global Marketing and Sales
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
10. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
11. Transcept Pharmaceuticals Appoints Key Senior Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The AMA is happy ... school graduates from across the nation. The scholarships are created through funds donated by ... , Scholarship criteria are set by the AMA Scholarship Committee, which is made up ...
(Date:4/20/2017)... ... April 20, 2017 , ... Assured Enterprises, Inc. ... offer a full spectrum of digital security goods and services. The strategic partners ... the ground-breaking proactive cybersecurity services and products through Assured Enterprises. The two companies ...
(Date:4/20/2017)... ... 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its ... in the learning technologies industry, Mastin joins NetDimensions from the New York office of ... At LEO, Mastin served as SVP of the North America offices and prior to ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and the ... sharing and commercialization model. , The Center for Advancing Innovation helps institutions maximize ... effort is bringing the IP to the attention of the entrepreneurial community and ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):